Search
for
Sort by
Research 30 of 106
- Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching
- Semaglutide and the Skin: An Overview of Current Evidence
- Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
- 53028 Semaglutide and Hair Loss: A Real-World Analysis
- Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
- Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
- GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
- Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review
- Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
- Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
- Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show